AR018186A1 - Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto - Google Patents

Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto

Info

Publication number
AR018186A1
AR018186A1 ARP990101770A ARP990101770A AR018186A1 AR 018186 A1 AR018186 A1 AR 018186A1 AR P990101770 A ARP990101770 A AR P990101770A AR P990101770 A ARP990101770 A AR P990101770A AR 018186 A1 AR018186 A1 AR 018186A1
Authority
AR
Argentina
Prior art keywords
compounds
spla2
carbazoly
tetrahydrocarbazol
inhibitors
Prior art date
Application number
ARP990101770A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR018186A1 publication Critical patent/AR018186A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP990101770A 1998-04-17 1999-04-16 Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto AR018186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
AR018186A1 true AR018186A1 (es) 2001-10-31

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990101770A AR018186A1 (es) 1998-04-17 1999-04-16 Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
ARP990101771A AR018593A1 (es) 1998-04-17 1999-04-16 COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990101771A AR018593A1 (es) 1998-04-17 1999-04-16 COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS

Country Status (30)

Country Link
EP (2) EP0950657B1 (https=)
JP (2) JP4435330B2 (https=)
KR (2) KR100586761B1 (https=)
CN (1) CN1149193C (https=)
AR (2) AR018186A1 (https=)
AT (2) ATE268756T1 (https=)
AU (2) AU753436B2 (https=)
BR (2) BR9901279A (https=)
CA (2) CA2269246C (https=)
CO (2) CO5031247A1 (https=)
CZ (2) CZ136999A3 (https=)
DE (2) DE69918590T2 (https=)
DK (1) DK0950657T3 (https=)
DZ (1) DZ2769A1 (https=)
EA (2) EA002347B1 (https=)
ES (2) ES2222663T3 (https=)
HU (2) HUP9901220A3 (https=)
ID (2) ID23761A (https=)
IL (2) IL129483A0 (https=)
NO (2) NO314400B1 (https=)
NZ (3) NZ335253A (https=)
PE (2) PE20000432A1 (https=)
PL (2) PL332565A1 (https=)
PT (1) PT950657E (https=)
SG (2) SG81977A1 (https=)
SI (1) SI0950657T1 (https=)
TR (2) TR199900853A2 (https=)
TW (1) TWI238160B (https=)
YU (2) YU19199A (https=)
ZA (2) ZA992772B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー sPLA2インヒビター
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
CA2441077A1 (en) 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
MX2010010471A (es) 2008-03-26 2010-10-20 Daiichi Sankyo Co Ltd Derivado de tetrahidroisoquinolina novedoso.
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
WO2010084402A2 (en) * 2009-01-22 2010-07-29 Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CA2889642A1 (en) * 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
KR20150088802A (ko) 2012-11-30 2015-08-03 지이 헬쓰케어 리미티드 트리시클릭 인돌 유도체의 결정화 방법
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
EP0779271B1 (en) * 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
CA2269203A1 (en) * 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
DZ2769A1 (fr) 2003-12-01
HU9901221A (hu) 2000-04-28
EP0952149A2 (en) 1999-10-27
EP0950657A2 (en) 1999-10-20
PE20000432A1 (es) 2000-05-23
TR199900853A3 (tr) 1999-11-22
CA2269246C (en) 2009-08-25
EA199900301A3 (ru) 2000-04-24
JP4435330B2 (ja) 2010-03-17
EA199900303A2 (ru) 1999-10-28
AR018593A1 (es) 2001-11-28
JPH11322713A (ja) 1999-11-24
HUP9901220A3 (en) 2001-11-28
ES2222663T3 (es) 2005-02-01
YU19199A (sh) 2002-08-12
NO991822L (no) 1999-10-18
AU2381999A (en) 1999-10-28
AU753436B2 (en) 2002-10-17
NO991822D0 (no) 1999-04-16
ATE268756T1 (de) 2004-06-15
CA2269262A1 (en) 1999-10-17
CZ137099A3 (cs) 1999-11-17
EA002816B1 (ru) 2002-10-31
NZ507564A (en) 2002-10-25
KR19990083233A (ko) 1999-11-25
SI0950657T1 (en) 2005-02-28
CA2269246A1 (en) 1999-10-17
PT950657E (pt) 2004-11-30
IL129485A0 (en) 2000-02-29
CO5011054A1 (es) 2001-02-28
DE69917833D1 (de) 2004-07-15
ID23761A (id) 2000-05-11
ES2226286T3 (es) 2005-03-16
ZA992772B (en) 2002-07-16
SG81977A1 (en) 2001-07-24
EP0952149A3 (en) 2001-08-16
ATE271037T1 (de) 2004-07-15
KR100586761B1 (ko) 2006-06-08
EA002347B1 (ru) 2002-04-25
YU18999A (sh) 2002-08-12
BR9901279A (pt) 2000-05-02
PE20000476A1 (es) 2000-06-02
TR199900853A2 (xx) 1999-11-22
JP2000026416A (ja) 2000-01-25
ID23287A (id) 2000-04-05
NZ335251A (en) 2000-11-24
IL129483A0 (en) 2000-02-29
EA199900301A2 (ru) 1999-10-28
PL332565A1 (en) 1999-10-25
NO314400B1 (no) 2003-03-17
NO991821D0 (no) 1999-04-16
ZA992771B (en) 2002-04-18
HU9901221D0 (en) 1999-06-28
TWI238160B (en) 2005-08-21
CN1149193C (zh) 2004-05-12
PL332566A1 (en) 1999-10-25
NO991821L (no) 1999-10-18
DE69918590T2 (de) 2005-07-21
EA199900303A3 (ru) 2000-04-24
TR199900843A2 (xx) 2000-02-21
EP0952149B1 (en) 2004-06-09
HU9901220D0 (en) 1999-06-28
NO312240B1 (no) 2002-04-15
KR19990083232A (ko) 1999-11-25
CZ136999A3 (cs) 1999-11-17
SG81976A1 (en) 2001-07-24
CO5031247A1 (es) 2001-04-27
EP0950657A3 (en) 2001-08-16
EP0950657B1 (en) 2004-07-14
HU9901220A (hu) 2000-04-28
NZ335253A (en) 2000-11-24
BR9902365A (pt) 2001-04-24
CN1253948A (zh) 2000-05-24
AU2381799A (en) 1999-10-28
DE69918590D1 (de) 2004-08-19
HUP9901221A3 (en) 2001-11-28
DK0950657T3 (da) 2004-11-22
DE69917833T2 (de) 2005-07-14
AU753547B2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
AR018186A1 (es) Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
GT199900115A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
RU95104885A (ru) 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
BR9713462A (pt) Métodos para produção de compostos carotenóides e óleos especiais em sementes de plantas.
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
PE44599A1 (es) Inhibidores de la enzima acido nitrico sintasa
AR013494A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
ES8106721A1 (es) Un metodo para la preparacion de derivados de ftalimidina
PE107999A1 (es) Derivados 3-amidinoanilina, inhibidores del factor x de coagulacion de la sangre activado e intermediarios de los mismos
ES2179823T3 (es) Inmunosupresor macrolido.
MX9402950A (es) Piridil-3-carbinoles 4-substituidos herbicidas.
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
ES2022446B3 (es) Derivados fenolicos de benzotiazol y su aplicacion como inhibidores de corrosion.
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
MX9305364A (es) Compuestos inhibidores de proteasa retroviral, metodo para su produccion y composicion farmaceutica que los comprende.
DE69918465D1 (de) Sulfonamidhydroxamate
CO5011061A1 (es) Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen
AR018185A1 (es) Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2
BR0012242A (pt) Composição de óleo para máquina de refrigeração
MX9304820A (es) Derivados de 1, 4-benzodioxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal